Subcostal Temporary Extracardiac Pacing II Study

Conduction Defect Clinical Trial

— STEP II  

Official title:

Subcostal Temporary Extracardiac Pacing II (STEP II) Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04374929
• Other study ID #: DOC-10084
• Status: Completed
• Phase: N/A
• Start date: July 28, 2020
• Est. completion date: May 14, 2021

Study information

• Verified date: June 2021
• Source: AtaCor Medical, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Up to 12 subjects will be enrolled (up to 8 undergoing an AtaCor Temporary Pacing System procedure) in order to evaluate initial safety and performance of the AtaCor Temporary Pacing System when used with three (3) strategies for stabilizing AtaCor Temporary Pacing System electrical measurements over a two (2) to seven (7) day period. The three treatments are (1) Negative Pressure Wound Therapy, (2) Anti-Inflammatory Glucocorticoid and (3) increased electrode spacing. A control arm with no additional treatment is also included. Safety will be evaluated through analysis of all Adverse Events. Performance will be evaluated through (1) the incidence of successful StealthTrac Lead placement using the MACH I Delivery Tool, (2) electrical performance measurements, such as pacing capture thresholds, sensed R-wave amplitudes, pacing impedance and skeletal muscle stimulation. Appropriate sensing and pacing capture will be ascertained from ECG Holter Monitor recordings during periods of in-hospital ambulation.

Description:

Enrolled Subjects will have both a market-released transvenous pacing lead and investigational StealthTrac Temporary Pacing Lead placed and evaluated. Following StealthTrac Lead insertion, each subject will receive (1) one of three (3) study treatments intended to stabilize pacing capture thresholds and pacing impedance over time or receive no treatment. The three treatments are (1) Negative Pressure Wound Therapy, (2) Anti-Inflammatory Glucocorticoid and (3) increased electrode spacing achieved by the use of two inserted StealthTrac Leads. During the placement procedure, diagnostic echocardiograms will be performed to detect any new pericardial effusions. Once inserted, the StealthTrac Lead will be used to deliver high rate pacing (160 to 220 BPM) in clinically appropriate Subjects, to demonstrate suitability for use in transcatheter procedures that require brief periods of temporary pacing. Lead positions will be documented using fluoroscopic images before the Subject leaves the procedure room. On the following two days after the procedure, electrical performance will be evaluated in multiple postures and appropriate pacing and sensing will be confirmed during activity using ECG Holter monitor recordings. Subjects will also be asked patient-centric questions about their experience with the StealthTrac Lead throughout the study period. Evaluations will continue for a maximum of seven (7) days after the index procedure. Prior to StealthTrac Lead removal, an X-Ray will be taken to document the final lead position. A final follow-up will be performed 25-30 days after removal to identify any latent adverse events before the Subject exits the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 7
• Est. completion date: May 14, 2021
• Est. primary completion date: December 15, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Indicated for closed-chest cardiac invasive procedure that does not require full systemic anticoagulation during the procedure.

Examples of such procedures include: transcatheter valve replacement, balloon valvuloplasty, implantable cardioverter-defibrillator (ICD) implantation, permanent pacemaker implantation and pacing lead extractions/revisions.

2. Physically and mentally capable of providing informed consent and at least 18 years of age or of legal age to provide consent as required by local and national requirements.

Exclusion Criteria:

1. History of a prior sternotomy (median or partial);

2. History of prior surgery with disruption of the lung, pericardium or connective tissue between the sternum and pericardium;

3. History of significant anatomic derangement of or within the thorax (e.g., pectus excavatum, significant scoliosis), prior chest radiation therapy or other reasons which may cause pericardial adhesions or complicate the AtaCor Temporary Pacing System insertion procedure;

4. History of pericardial disease, pericarditis or mediastinitis;

5. History of chronic obstructive pulmonary disease (COPD);

6. NYHA functional classification IV at the time of enrollment;

7. History of congenital heart disease;

8. Patients with circumstances that prevent data collection or follow-up;

9. BMI > 35 kg/m2;

10. Contraindication to glucocorticoid medication;

11. History of allergies to any study devices; and

12. Participation in any concurrent study without prior, written approval from the Sponsor.

Related Conditions & MeSH terms

• Conduction Defect

Intervention

Device:
• StealthTrac Temporary Pacing Lead Plus Negative Pressure Wound Therapy
Following fixation of the StealthTrac Lead, Negative Pressure Wound Therapy is applied over the incision site.
• StealthTrac Temporary Pacing Lead Plus Anti-Inflammatory Glucocorticoid
• Methylprednisolone 125 mg administered over 30 minutes beginning at least 30 minutes prior to the incision and StealthTrac Lead insertion procedure. This intravenous dose can be repeated every 8 hours on day one of the insertion from 1-3 doses depending on the patient's ability to take oral medications. It can be administered daily thereafter until the patient is able to take oral dosing. In normal circumstances, post op day 2, commence oral glucocorticoid (see below for recommended oral dosing). Oral (PO) glucocorticoid preparations and dosing: Prednisone 40-60 mg orally daily based on BMI category. BMI categories: Low (<18); Medium (18-30); High (>30). Low and medium are assigned 40 mg daily. High BMI is assigned 60 mg daily dose. This while the StealthTrac lead remains in place. Methylprednisolone 16-32 mg daily based on BMI (low, medium and high) while the StealthTrac Lead remains in place.
• Two StealthTrac Temporary Pacing Leads (Increased Electrode Spacing)
Once the first StealthTrac Lead is placed using the procedure described in the AtaCor Temporary Pacing System Instructions for Use (DOC-10085), load a second StealthTrac Lead into the same MACH I Delivery Tool, unless it was damaged during insertion of the first StealthTrac Lead, in which case a new MACH I Delivery Tool should be used. Insert the second StealthTrac Lead through (1) a different intercostal muscle path within the same intercostal space or (2) within an adjacent intercostal space. Increased electrode spacing is achieved by pacing between the leads.
• StealthTrac Lead Only (Control)
A single StealthTrac Lead is placed with no additional treatment.

Locations

Country	Name	City	State
New Zealand	Christchurch Hospital	Christchurch
Paraguay	Sanatorio Italiano	Asunción

Sponsors (1)

Lead Sponsor	Collaborator
AtaCor Medical, Inc.

Countries where clinical trial is conducted

New Zealand,  Paraguay, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety Outcome: Number of Subjects Experiencing an Adverse Device Effect	Number of Subjects Experiencing an Adverse Device Effect	30 days
Primary	Performance Outcome	Mean Pacing Capture Threshold (V)	Up to 7 days post insertion
Primary	Performance Outcome	Mean Pacing Impedance (Ohms)	Up to 7 days post insertion
Primary	Performance Outcome	Mean R-Wave Amplitude (mV)	Up to 7 days post insertion